Cellectis SA
PAR:ALCLS
Cellectis SA
Cellectis SA engages as a biopharmaceutical company that harnesses the immune system to target and eradicate cancer cells. The company is headquartered in Paris, Ile-De-France and currently employs 345 full-time employees. The company went IPO on 2007-02-06. The firm specializes in the research, development, and commercialization of rational genome engineering technologies. The firm develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. The company has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The firm operates in France and the United States, among others.
Cellectis SA engages as a biopharmaceutical company that harnesses the immune system to target and eradicate cancer cells. The company is headquartered in Paris, Ile-De-France and currently employs 345 full-time employees. The company went IPO on 2007-02-06. The firm specializes in the research, development, and commercialization of rational genome engineering technologies. The firm develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. The company has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The firm operates in France and the United States, among others.
Phase II Progress: Cellectis is set to initiate a pivotal Phase II trial for lasme-cel (UCART22) in relapsed/refractory acute lymphoblastic leukemia during the second half of 2025, following positive feedback from the FDA and EMA.
R&D Day Announcement: An in-person Investors R&D Day is scheduled for October 16, 2025, in New York City, where the company will present full Phase I data and late-stage development plans for lasme-cel.
Cash Runway: The company reported $230 million in cash, cash equivalents, and deposits as of June 30, 2025, and expects this to fund operations into the second half of 2027, including pivotal studies.
NatHaLi-01 Update: Phase I data for the eti-cel (UCART20x22) program in non-Hodgkin lymphoma will be shared in late 2025, with Phase II preparations targeted for 2026.
Regulatory Alignment: Management emphasized strong alignment and productive interactions with both FDA and EMA regarding Phase II trial design and endpoints.
Servier Arbitration: An arbitration decision with Servier regarding CD19 products is expected by December 15, 2025, with Cellectis seeking agreement termination and compensation.
AstraZeneca Partnership: Research continues on three cell and gene therapy programs under a joint agreement with AstraZeneca, covering both hematological malignancies and solid tumors.
